1. Introduction
===============

Chronic pain states continue to represent debilitating illnesses with a significant unmet clinical need. Amongst potential new therapeutic leads, agents that activate PKC have been proposed as anti-nociceptive agents \[[@B1-pharmaceuticals-06-00777]\]; in this regard, phorbol esters, which are a class of non-hydrolysable analogues of diacylglycerol, activate PKC experimentally. In a related manner, targeting presynaptic VDCCs in nociceptive pathways is another potentially beneficial therapeutic avenue \[[@B2-pharmaceuticals-06-00777],[@B3-pharmaceuticals-06-00777]\]. VDCCs may be divided into three major families, Ca~V~1-3; the Ca~V~2 family (Ca~V~2.1, Ca~V~2.2 and Ca~V~2.3) are predominantly localised to presynaptic nerve terminals, where they control transmitter release and different aspects of synaptic plasticity \[[@B4-pharmaceuticals-06-00777],[@B5-pharmaceuticals-06-00777],[@B6-pharmaceuticals-06-00777]\]. Within the dorsal horn of the mammalian spinal cord, Ca~V~2.1 and Ca~V~2.2 subunits are strongly expressed in presynaptic terminals, whilst there is also evidence for presynaptic expression of Ca~V~2.3 subunits in nociceptive pathways \[[@B7-pharmaceuticals-06-00777],[@B8-pharmaceuticals-06-00777],[@B9-pharmaceuticals-06-00777]\]. The phorbol ester/PKC pathway has been proposed to phosphorylate Ca~V~2 subunits in expression systems \[[@B10-pharmaceuticals-06-00777],[@B11-pharmaceuticals-06-00777],[@B12-pharmaceuticals-06-00777],[@B13-pharmaceuticals-06-00777]\]. The molecular determinants for the phorbol ester/PKC pathway include sites on the intracellular linker between domains I and II (the I-II loop) of Ca~V~2 subunits, this pathway is involved in regulating transmitter release, potentially by opposing inhibitory G protein modulation, as reviewed in \[[@B14-pharmaceuticals-06-00777],[@B15-pharmaceuticals-06-00777]\]. This dynamic regulation may be therapeutically targeted in nociceptive pathways. However, phorbol esters may also activate other "non-kinase" C1 domain-containing receptors \[[@B16-pharmaceuticals-06-00777]\]; therefore, a major aim of this study was to determine if a phorbol ester pathway involving Ca~V~2 VDCCs operates in nociceptive pathways.

We have previously shown that isolated dorsal root ganglia (DRG) neurones associated with the Aδ and C fibres that supply laminae I and II in the dorsal horn contain Ca~V~2.1, Ca~V~2.2 and Ca~V~2.3 current components (as defined by sensitivity to selective pharmacological agents) \[[@B17-pharmaceuticals-06-00777]\]. Moreover, *in vivo* electrophysiological recording from wide-dynamic range neurones located in rat lamina V dorsal horn suggest that Ca~V~2.2, and to a lesser extent Ca~V~2.1, channels contribute to basal synaptic transmission, and that contributions of Ca~V~2.2 are increased under neuropathic conditions \[[@B18-pharmaceuticals-06-00777]\]. Ca~V~2.3 plays only a minor role to basal transmission at WDR neurones, but neuropathy also causes a clear increase in Ca~V~2.3 contribution to nociceptive transmission \[[@B19-pharmaceuticals-06-00777]\]. Here, we demonstrate that Ca~V~2.1, Ca~V~2.2 and Ca~V~2.3 subunits represent molecular targets in phorbol ester-stimulated increases in nociceptive transmission onto lamina II dorsal horn neurones; such findings are consistent with a pathway involving phorbol ester/PKC modulation of VDCCs in the mammalian spinal cord.

2. Experimental Section
=======================

2.1. Acute spinal Cord Slice Preparation and Solutions
------------------------------------------------------

Spinal cord slices were prepared from three to four week-old male litter-matched C57Bl/6 wild type or Ca~V~2.3(−/−) mice \[[@B20-pharmaceuticals-06-00777]\]. Mice were anesthetized by isofluorane inhalation and humanely killed by cervical dislocation and decapitated, in line with UK Home Office procedures \[Animals (Scientific Procedures) Act 1986\] and as approved by Local Ethical Review Panel. A lumbar laminectomy was performed and the spinal cord was gentled excised under pressure from a syringe filled with ice-cold sucrose-based artificial cerebrospinal fluid (aCSF) solution containing (in mM): sucrose 124, KCl 3, NaHCO~3~ 26, NaH~2~PO~4~ 2.5, MgSO~4~ 2, CaCl~2~ 2, D-glucose 10 (pH 7.3). The spinal cord was placed in a shallow-grooved agarose block which was glued to the stage of a Vibroslice 725M (Campden Instruments Ltd, Loughborough, UK) and transverse slices (300 μM) cut in ice-cold sucrose-based aCSF bubbled with 95% O~2~/5% CO~2~. Slices were transferred into standard aCSF solution contained (in mM): NaCl 124, KCl 3, NaHCO~3~ 26, NaH~2~PO~4~ 2.5, MgSO~4~ 2, CaCl~2~ 2, D-glucose 10, maintained at pH 7.3 by bubbling with 95% O^2^ / 5% CO~2~ at 37 °C for 1 h and then maintained at room temperature (20--24 °C).

2.2. Electrophysiological Recording
-----------------------------------

Spinal cord slices were transferred to a recording chamber on an upright Olympus BX50WI microscope (Olympus, Tokyo, Japan) and perfused at 2--4 mL min^−1^ with standard carboxygenated aCSF at room temperature. The high neuronal density allowed identification of laminae II, where individual dorsal horn neurones were visualised using differential interference contrast optics with a 60x water immersion lens. Whole-cell patch clamp recordings were performed using an EPC-10 patch-clamp amplifier (HEKA Electronik, Lambrecht, Germany), controlled by PatchMaster software (HEKA). Patch electrodes were fabricated from borosilicate glass (GC150-F10, Harvard Apparatus, Kent, UK) using a Flaming Brown P-87 micropipette puller (Sutter Instruments Company, Novato, CA, USA) and fire-polished using a MF-830 Microforge (Narashige, Tokyo, Japan). Electrodes had resistances 7-8 MΩ when filled with an intracellular solution \[containing (in mM): CsCl 140, MgCl~2~ 1, CaCl~2~ 1, EGTA 10, MgATP 4, NaGTP 0.4, HEPES 10, pH 7.3 with CsOH\]. Series resistance was typically less than 20 MΩ and compensated by 70%--90% throughout. Data were sampled at 7 kHz and filtered at one-third of the sampling frequency. In this study, rapidly activating, inward currents at a holding potential of −70 mV were designated as sPSCs. In the present brief report we did not attempt to distinguish between effects on inhibitory glycinergic or GABAergic or excitatory glutamatergic transmission. Data were analysed using FitMaster (HEKA), Axograph (Molecular Devices, Sunnyvale, CA, USA) and Excel (Microsoft, Redmond, WA, USA) software. Cumulative frequency plots were constructed for sPSC inter event intervals using 5 ms bins. sPSC frequency data were normalised to control period (0--5 mins prior to drug treatment) and measured at steady-state (10--15 mins after drug treatment). Effects on sPSC amplitude (as a measure of effects on postsynaptic receptor sensitivity) and on sPSC half-width (as a measure of effects on clearance of transmitter from the synaptic cleft *i.e.*, a reflection of any change in timecourse of event decay) were also determined. Data are presented as mean value ± S.E.M. Statistical significance was determined using Student\'s paired or unpaired *t*-tests, Kolmogorov-Smirnov (KS) tests or Mann-Whitney U-tests, as described in text. In all cases, *p* \< 0.05 was considered significant.

2.3. Pharmacology
-----------------

The following agents were purchased: PMA (Sigma, Poole, UK); ω-conotoxin GVIA (Alomone Labs, Jerusalem, Israel); ω-agatoxin IVA (Sigma); SNX-482 was a kind gift from Alomone Labs. All drugs were made up at 1000 x stocks in distilled water, except PMA, which was dissolved in DMSO. Stocks were aliquoted and stored at −20 °C. Aliquots were thawed and dissolved in carboxygenated aCSF immediately prior to use.

3. Results and Discussion
=========================

3.1. Effect of PMA on Synaptic Transmission in Dorsal Horn Neurones
-------------------------------------------------------------------

Whole-cell recordings were made from visually identified laminae II dorsal horn neurones within the substantia gelatinosa in spinal cord slices. Bath application of the phobol ester PMA (2 µM) caused a significant increase in mean sPSC frequency ([Figure 1](#pharmaceuticals-06-00777-f001){ref-type="fig"}A,C,E,F, [Table 1](#pharmaceuticals-06-00777-t001){ref-type="table"}), but was without effect on mean sPSC amplitude ([Figure 1](#pharmaceuticals-06-00777-f001){ref-type="fig"}B, [Table 1](#pharmaceuticals-06-00777-t001){ref-type="table"}) and half-width ([Figure 1](#pharmaceuticals-06-00777-f001){ref-type="fig"}D, [Table 1](#pharmaceuticals-06-00777-t001){ref-type="table"}). Phorbol esters such as PMA are widely used to activate PKC isoforms, a family of at least 10 serine/threonine kinases that have been proposed as major regulators of sensitization in chronic pain states \[[@B1-pharmaceuticals-06-00777]\]. For example, phorbol ester-activated PKC isoforms are known to be up-regulated in dorsal horn neurones in response to noxious stimuli \[[@B21-pharmaceuticals-06-00777]\]. Treatment with phorbol esters has been widely used to implicate PKC isoforms as phosphorylating agents at VDCCs, such actions potentiate Ca^2+^ current \[[@B10-pharmaceuticals-06-00777],[@B22-pharmaceuticals-06-00777]\], consistent with phorbol ester-induced increases in vesicular release seen here. However, PMA/PKC phosphorylation pathways also have potential to target other ion proteins at nociceptive presynaptic terminals, including AMPA, NMDA and kainate ionotropic receptors, transient receptor potential channel subtypes \[[@B23-pharmaceuticals-06-00777],[@B24-pharmaceuticals-06-00777],[@B25-pharmaceuticals-06-00777]\] and, also, other C1 domain-containing receptors potentially involved in exocytosis \[[@B26-pharmaceuticals-06-00777],[@B27-pharmaceuticals-06-00777]\]. Such studies suggest that phorbol ester-mediated effects on synaptic transmission may occur, at least in part, independently of effects on VDCCs; therefore, a major aim of the present study was to investigate whether (i) presynaptic Ca~V~2 VDCCs mediate PMA effects in nociceptive pathways and (ii), if so, which Ca~V~2 subtypes are predominantly involved.

![Effects of PMA on nociceptive transmission in dorsal horn neurones. (**A**) Raw data traces showing effects of PMA (2 M) on control sPSCs (holding potential (V~H~) = −70 mV). Box and whisker plots showing effects of PMA (2 μM) on (**B**) sPSC amplitude (**C**) sPSC frequency and (**D**) sPSC half-width. In these plots, the median value is represented by central bars, 25% and 75% quartile ranges depicted by boxes, max/min values represented by "error" bars. (**E**) Bar graph showing summarised effects of PMA (2 μM) on normalised sPSC frequency. (**F**) Cumulative frequency plots for effect of PMA (2 μM) on control sPSC inter event interval; data sets significantly different using *KS*-test. (B--F) *n* = 6 ± S.E.M., \* = *p* \< 0.05 (Mann Whitney *U*-test).](pharmaceuticals-06-00777-g001){#pharmaceuticals-06-00777-f001}

pharmaceuticals-06-00777-t001_Table 1

###### 

Effects of PMA on sPSCs in dorsal horn neurones in litter-matched WT and Ca~V~2.3(−/−) mice.

                          sPSC amplitude (pA)   sPSC frequency (Hz)   sPSC half-width (ms)
  ----------------------- --------------------- --------------------- ----------------------
  WT (n = 6)              43.5 ± 4.2            0.69 ± 0.16           6.85 ± 0.57
  PMA (n = 6)             41.8 ± 5.0            1.40 ± 0.36 \*        6.72 ± 0.47
  Ca~V~2.3(−/−) (n = 8)   57.3 ± 9.7            1.00 ± 0.15           7.26 ± 0.42
  PMA (n = 8)             47.4 ± 5.3            1.08 ± 0.21           7.27 ± 0.40

No significant differences were seen in basal sPSC properties between dorsal horn neurones from WT and Ca~V~2.3(−/−) mice (Student\'s unpaired *t*-tests). PMA caused a significant increase in sPSC frequency in dorsal horn neurones from WT, but not Ca~V~2.3(−/−) mice. **\***= *p* \< 0.05 *vs* control (WT) (Student's paired *t*-test).

3.2. Contribution of Ca~V~2 VDCC Subtypes to PMA Effects on Synaptic Transmission in Dorsal Horn Neurones
---------------------------------------------------------------------------------------------------------

Bath application of 200 nM AgTX ([Figure 2](#pharmaceuticals-06-00777-f002){ref-type="fig"}A,B), 1 μM CTX; ([Figure 2](#pharmaceuticals-06-00777-f002){ref-type="fig"}C,D) or 300 nM SNX-482 ([Figure 2](#pharmaceuticals-06-00777-f002){ref-type="fig"}E,F) each caused a significant inhibition in mean sPSC frequency; none of these selective VDCC blockers had significant effects on mean sPSC amplitude or half-width (data not shown). Initially, these data are consistent with high-voltage-activated Ca~V~2.1, Ca~V~2.2 and Ca~V~2.3 VDCC subtypes each contributing to nociceptive transmission in lamina II dorsal horn neurones. In line with such observations, intrathecal injection of AgTX, CTX or SNX-482 has been shown to have anti-nociceptive effects *in vivo*, also consistent with immunohistochemistry localization of Ca~V~2 family subunits to the dorsal horn of the spinal cord \[[@B8-pharmaceuticals-06-00777]\]. Presynaptic Ca~V~2.2 (N-type) Ca^2+^ channels have been shown to make a major contribute to nociception \[[@B18-pharmaceuticals-06-00777],[@B28-pharmaceuticals-06-00777]\] and mediate excitatory glutamate release onto laminae I/II dorsal horn neurones \[[@B29-pharmaceuticals-06-00777],[@B30-pharmaceuticals-06-00777],[@B31-pharmaceuticals-06-00777]\] and play a major role in opioid-mediated inhibition \[[@B32-pharmaceuticals-06-00777]\]; in these studies, Ca~V~2.1 (P/Q-type current) subunits also play, an albeit more minor, role. A CTX- and AgTx-resistant (R-type) Ca^2+^ current component in dorsal horn neurones, potentially due to Ca~V~2.3 subunits, has also been reported \[[@B31-pharmaceuticals-06-00777]\]. We have previously shown that Ca~V~2.3 subunits contribute to R-type Ca^2+^ current in DRGs cells and that Ca^2+^ currents encoded by Ca~V~2.3 subunits are blocked by SNX-482 \[[@B17-pharmaceuticals-06-00777]\]. Although much less is known about the contribution of Ca~V~ subtypes to inhibitory transmission, Rycroft and co-workers \[[@B31-pharmaceuticals-06-00777]\] reported that N-type currents contribute to evoked IPSCs in lamina I neurones, however, unlike for excitatory inputs, this contribution was unchanged under neuropathic conditions. Finally, it is worth pointing out that low-voltage-activated, T-type Ca~V~3.2 channels have also been shown to contribute to nociceptive transmission in the dorsal horn neurones \[[@B33-pharmaceuticals-06-00777]\].

Bath application of 2 μM PMA in the continued presence of either 200 nM AgTX ([Figure 2](#pharmaceuticals-06-00777-f002){ref-type="fig"}A,B), 1 μM CTX; ([Figure 2](#pharmaceuticals-06-00777-f002){ref-type="fig"}C,D) or 300 nM SNX-482 ([Figure 2](#pharmaceuticals-06-00777-f002){ref-type="fig"}E,F) had no effect on mean sPSC frequency; under these conditions, 2 μM PMA also had no effect on mean sPSC amplitude or half-width (data not shown). These data implicate different Ca~V~2 VDCCs as mediators of PMA effects on nociceptive transmission in the dorsal horn. It is of interest that blockade of an individual Ca~V~2 subtype was sufficient to removal the stimulatory effect of PMA; this sensitivity suggests that, in terms of PKC response, there is a lack of Ca~V~2 subtype redundancy within this system. Phorbol esters have been used to implicate serine and threonine residues in the VDCC I-II loop and C-terminal as important determinants for PKC-mediated potentiation of Ca^2+^ current in Ca~V~2.2 and Ca~V~2.3 channels \[[@B10-pharmaceuticals-06-00777],[@B11-pharmaceuticals-06-00777],[@B12-pharmaceuticals-06-00777],[@B13-pharmaceuticals-06-00777]\]. Ca~V~2.1 subunits were reported to be unaffected by PMA \[[@B10-pharmaceuticals-06-00777],[@B22-pharmaceuticals-06-00777]\]; however, this effect may be dependent on the PKC isoform activated, the availability of isoform-dependent phosphorylation sites or even the channel environment, as these experiments were performed in expression systems. In regard to the latter, there is evidence that AgTx attenuates PMA-mediated increases in transmitter release at the neuromuscular junction \[[@B34-pharmaceuticals-06-00777],[@B35-pharmaceuticals-06-00777]\] and we have previously shown that phorbol esters cause a significant increase in inhibitory synaptic transmission at the interneurone-Purkinje cells pathway in the cerebellum \[[@B36-pharmaceuticals-06-00777]\], synapses at which Ca~V~2.1 channels dominate the control of transmitter release \[[@B37-pharmaceuticals-06-00777]\]. The functional data presented here suggest that PMA can exert effects on endogenous AgTx-sensitive Ca~V~2.1 channels in nociceptive pathways.

Original studies using cloned, isolated ion channels in expression systems by Newcomb and co-workers \[[@B38-pharmaceuticals-06-00777]\], have prompted researchers to use 300 nM SNX-482 as a selective concentration for Ca~V~2.3 over other channels, including Cav2.1; however, Arroyo *et al.* \[[@B39-pharmaceuticals-06-00777]\] have suggested that 300 nM SNX 482 may also affect Cav2.1; therefore, the effects of PMA were also examined in Ca~V~2.3(−/−) mice. In this regard, Ca~V~2.3(−/−) mice were shown to have selective alterations in behavioural pain responses \[[@B40-pharmaceuticals-06-00777]\]. 2 μM PMA was without effect on mean sPSC frequency ([Figure 2](#pharmaceuticals-06-00777-f002){ref-type="fig"}G,H), amplitude or half-width ([Table 1](#pharmaceuticals-06-00777-t001){ref-type="table"}) in Ca~V~2.3(−/−) mice. These genetic deletion data support pharmacological data implicating a role for Ca~V~2.3 subunits in PMA actions. In our experiments, genetic deletion of Ca~V~2.3 *per se* had no clear effect on mean sPSC frequency, amplitude or half-width in comparison to litter-matched wild-type mice used in the experiments above ([Table 1](#pharmaceuticals-06-00777-t001){ref-type="table"}). This may be unexpected in relation to the reduction in sPSC frequency seen for SNX-482 above and we cannot rule out a compensatory upregulation of other Ca~V~2 isoforms; alternatively, we previously reported that small proportion of DRG Ca^2+^ current in mice lacking Ca~V~2.3 is sensitive to SNX-482 \[[@B17-pharmaceuticals-06-00777]\], so it possible that SNX-482 may also be blocking further VDCC targets here.

![Contribution of Ca~V~2 VDCC subtypes to PMA effects on nociceptive transmission in dorsal horn neurones. Bar graphs showing summarised effects of selective VDCC blockers effects on normalised sPSC frequency and PMA (2 µM) actions in the presence of (**A**) 200 nM AgTx (n = 6 ± S.E.M.), (**C**) 1 µM CTX (n = 6 ± S.E.M.) and (**E**) 300 nM SNX-482 (n = 6 ± S.E.M.). (**G**) Bar graph showing summarised effects of PMA (2 μM) effects on normalised sPSC frequency in Ca~V~2.3(−/−) mice (n = 8 ± S.E.M.). In all cases, \* = *p* \< 0.05 (Mann Whitney *U*-test). Cumulative frequency plots showing summarised effects of selective VDCC blockers effects on sPSC inter event interval and PMA (2 μM) actions in the presence of (**B**) 200 nM AgTx (n = 6 ± S.E.M.), (**D**) 1 μM CTX (n = 6 ± S.E.M.) and (**F**) 300 nM SNX-482 (n = 6 ± S.E.M.); each blocker caused a significant decrease in inter event interval, PMA had no further effect in each case using *KS*-tests. (H) Cumulative frequency plot showing summarised effects of PMA (2 μM) effects on normalised sPSC frequency in Ca~V~2.3(−/−) mice (n = 8 ± S.E.M.); data sets not significantly different using *KS*-test.](pharmaceuticals-06-00777-g002){#pharmaceuticals-06-00777-f002}

4. Conclusions
==============

The major conclusions of this brief report are that different Ca~V~2 VDCC subtypes contribute to nociceptive transmission in lamina II dorsal horn neurones and that these Ca~V~2 channels represent molecular targets for the stimulatory effects of PMA on nociceptive transmission; we also indicate a lack of Ca~V~2 subtype redundancy in terms of PMA responses. A potential mechanism whereby PMA exerts effects is via the activation of PKC isoforms, leading to phosphorylation of presynaptic Ca~V~2 subunit in dorsal horn neurones to modulate excitability. Here, we record mixed sPSC responses to determine overall PMA effects on nociceptive transmission; in the future, it will be important to determine PMA actions on different inhibitory glycinergic or GABAergic and/or excitatory glutamatergic pathways and, also, to determine if other Ca~V~ channels are a further target for PMA effects on nociceptive transmission in the continuing search for novel therapeutic targets in pain.

We would like to thank Alasdair Gibb (Neuroscience, Physiology and Pharmacology University of London) for initially help with spinal cord slice preparation. This work was supported by the BBSRC (GJS and LY) and by the National Natural Science Foundation of China (LY) No.81102901.

The authors declare no conflict of interest.
